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There is predominate opinion among physicians managing type 1 Gauchers’ disease (GD) that cardiac involvement is not an
issue in these patients. In order to follow this hypothesis, we prospectively investigated 15 adult imiglucerase-treated type 1 GD
patients by echocardiography, Doppler, and tissue Doppler echocardiography. This was a case-controlled study with 18 matched
healthy volunteers. The obtained data was correlated with the levels of NT-proBNP (brain natriuretic peptide). None of the GD
patients had clinical signs of heart disease. In 3 of the 15 patients, we observed echocardiographic signs of aortic and mitral
valve calciﬁcation. The left ventricular systolic function was within normal limits. Compared to the control group, there was
no statistically signiﬁcant diﬀerence observed in the most sensitive indices of left ventricular diastolic function, parameter Em
(P = .095), and E/Em ratio (P = .097), as demonstrated by tissue Doppler echocardiography. However, there was a positive
correlation between the E/Em ratio and NT-proBNP plasma levels (P = .009). In conclusion, the prospective echocardiographic
study of type 1 GD patients did not validate any left ventricular dysfunction. But, the E/Em ratio showed a strong statistical
correlation with the most sensitive indicators of heart failure, NT-proBNP. Research on larger groups of patients and the usage of
even more sensitive methods as strain-rate imaging will be necessary to conﬁrm eventual myocardial involvement in GD patients.
1.Introduction
Gaucher’s disease (GD) is an autosomal recessive inherited
defect of lysosomal enzyme beta-glucosidase, which leads to
glucocerebroside accumulation in various organs, especially
those of the reticuloendothelial system (RES). The fact is
that the cells of RES are present in every human organ
and consequentially we could expect that virtually every
human organ may be involved. Nevertheless, the heart is not
thought to be involved in type 1 GD. Meanwhile, there is an
exception regarding type 3 GD (characterised by nonacute
neurological involvement) in which aortic cusps and mitral
leaﬂets may show calciﬁcations on light microscopy, and
Gaucher’s cells were conﬁrmed in the lesions by electron
microscopy [1–6]. Homozygosity for the D409H mutation
has been associated with speciﬁc cardiovascular symptoms
[6]. Constrictive pericarditis has been described in patients
with type 1 GD, but no Gaucher’s cells have been found in
the pericardium [7–9].
There are few reports of pulmonary hypertension in type
1G D[ 9]. The ﬁrst one includes the inﬂuential description of
pericarditis in Gaucher’s disease and pulmonary hyperten-
sion [10]. In most cases the alveolar spaces and interstitial
tissue were inﬁltrated with Gaucher’s cells. In addition,
Gaucher cells may occlude pulmonary capillaries resulting in
pulmonaryhypertension.Pulmonarydiseaseisawell-known
complication of type 1 GD, although its incidence is not well
established and its severity varies [11–13].
Left ventricular dysfunction has been described in rare
cases of GD [14]. However, systematic echocardiographic
evaluation is lacking. We investigated patients with type
1 GD by echocardiography, Doppler, and tissue Doppler
echocardiography. We paid special attention to heart valve
diseases, eventual signs of pulmonary hypertension, and left
ventricular function. Afterwards we correlated the parame-
tersofleftventricularfunctionwiththelevelsofNT-proBNP,
the most sensitive biochemical marker of heart failure [15].2 Advances in Hematology
2. Methods
2.1. Patients. In our study we included all patients with type
1 GD gathered in the adult’s database at University Medical
Centre, Ljubljana, which is the only centre for treating
adults with this metabolic storage disorder in Slovenia.
Glucocerebrosidase gene mutation analysis was performed
in all patients, and neither homozygote nor heterozygote
was found with present D409H mutation. All type 1 GD
patientsunderstudyarereceivingimigluceraseforatleastﬁve
years, and the majority of patients started with imiglucerase
seven years before our study was performed. In all of
them the therapy is eﬀective, regarding both clinical and
laboratory aspects. Before treatment with imiglucerase was
instituted, each separate patient was evaluated individually.
Nevertheless,everyoneofthematthattimepointhadatleast
anemiaandthrombocytopenia,hepatomegaly,splenomegaly
(if spleen was not already surgically removed), and clear
clinical symptoms and radiological signs of bone disease.
Their pretreatment chitotriosidase levels were between 2900
to 13300nmol/L/h. All patients were completely ﬁt for the
indications for imiglucerase therapy because of the extent of
thedisease[16].Atthesametimenoneofthetreatedpatients
have had clinical signs of lung involvement characterised by
dyspnoea as a leading symptom.
We prospectively studied 15 adults, 7 males and 8
females, aged from 21 to 71 years, with a mean age of 40
(plus or minus 15 years). As the control group, we assembled
18 healthy volunteers matched for sex and age, without any
history of cardiovascular disease, diabetes mellitus, or hyper-
tension.Highlytrainedathleteswereexcluded.Theirphysical
examinations and resting 12-lead electrocardiograms, were
all within normal limits. The study was approved by the
Slovenian Medical Ethics Committee and conforms to the
principles outlined in the Declaration of Helsinki.
2.2. Clinical Investigation. The patients and control subjects
underwent detailed clinical evaluation, including a review of
medical history and physical examination. Historical data
included the position of the patient within the functional
classiﬁcation of the New York Heart Association (NYHA).
We also analysed standard 12-lead electrocardiograms.
2.3. Echocardiography. Transthoracic cross-sectional echo-
cardiography, echo-Doppler studies, and tissue Doppler
echocardiography were carried out using a Hewlett-Packard
Sonos 5500 echocardiographic machine. Dimensions of the
left ventricle were measured in the parasternal short-axis
view and left ventricular ejection fraction was calculated
by Teicholz formula [17, 18]. The degree of tricuspid
regurgitation,assessedbycolourﬂowDoppler,wasestimated
asmild,moderate,orseverebythewidthandlengthofthejet
[19, 20]. The following diastolic parameters were measured:
E/A ratio, pulmonary vein SD ,A velocities, duration of A
seen on the pattern of transmitral ﬂow pattern (A dur) and
on the pulmonary venous ﬂow (a dur). The ratio of duration
of A to a was calculated [21].
Pulsed-tissue Doppler echocardiographic images were
recorded from the apical 4-chamber view. Maximal systolic
(Sm), early (Em), and late (Am) diastolic peak velocities
were measured. For assessing the velocity of longitudinal
excursion of the left ventricle, a sample volume was placed
at the mitral annulus at the basal segment of the muscular
ventricular septum (Sm,Em,Am). For each subject, at least
three consecutive cardiac cycles were analysed and averaged.
2.4. Plasma NT-proBNP. Samples were obtained from the
antecubital vein in all subjects. Blood was collected into
chilled tubes containing preservative, promptly centrifuged,
and stored at −70
◦C until ﬁnal analysis. Levels of NT-
proBNP in the serum were measured by the electro-
chemiluminescence immunoassay using a Roche Elecsys
immunoassay analyzer (Roche Diagnostics GmbH D-68298
Mannheim). The measuring range of 5 to 35.000ng/L was
deﬁned by the lower detection limit and the maximum of the
master curve. The cutoﬀ value for normality was 125ng/L
[22].
2.5. Statistical Analysis. Numerical variables are presented
as the mean ±SD. The parameter values were tested for
normal distribution with the Kolmogorov-Smirnov test.
Associations among normally distributed variables were
evaluated by calculating Pearson correlation coeﬃcients,
and the Spearman correlation coeﬃcient was used when
diﬀerences were not distributed normally. Statistical analyses
were performed with the SPSS software package (version
13.0).
3. Results
3.1. Clinical Investigation and ECG. All enrolled patients had
normal baseline cardiovascular status. None of the patients
developed overt heart failure, and all of them were in
functional class I by NYHA. All patients were in regular sinus
rhythm without any signs of right ventricular hypertrophy.
3.2. Echocardiography. I no n eG Dp a t i e n t ,t h e r ew e r e
echocardiographicsignsofminimalaorticvalvecalciﬁcation,
another one had minor calciﬁcations of the mitral annulus
while one patient showed both aortic cusps and mitral
annular calciﬁcations. All three patients were the oldest
patients in the group (56, 63, and 71 years). Some mild
calciﬁcations of aortic cusps were found only in the oldest
control subject (71 years of age).
No echocardiographic abnormalities have been seen in
the pericardial area. None of the patients showed any signs
of pulmonary hypertension. Only 2/15 (64 and 21 years)
patients had no more than noticeable tricuspid regurgitation
with tricuspid regurgitation ﬂow velocity less than 2.5m/s.
Echocardiographic parameters of left ventricular systolic and
diastolic functions are indicated in Table 1.
3.3. Correlation between Cardiac Markers and Echocardio-
graphic Variables. Correlation was assessed between bio-
chemical (NT-proBNP) and echocardiographic parametersAdvances in Hematology 3
Table 1: Echocardiographic parameters in patients and controls.
Patients
n = 15
Control subjects
n = 18
P value
LV EF (%) 70.7±7.51 64.2 ±3.42 NS
E (cm/s) 88±17 91 ±19 NS
A (cm/s) 66 ±13 65 ±16 NS
E/A 1.36 ±0.35 1.46 ±0.44 NS
S (m/s) 0.59 ±0.09 0.59 ±0.14 NS
D (m/s) 0.56 ±0.11 0.63 ±0.14 NS
S/D 1.07 ±0.27 0.96 ±0.25 NS
A dur (ms) 125 ±19 139 ±26 NS
a dur (ms) 96 ±19 101 ±22 NS
A/a 1.34 ±0.27 1.44 ±0.32 NS
Sm (cm/s) 8.2 ±1.28 .5 ±0.9 NS
Em (cm/s) 11.2 ±4.11 3 .3 ±2.8 0.095
∗
Am (cm/s) 9.8 ±2.09 .4 ±1.9 NS
E/Em 8.8 ±3.37 .3 ±1.8 0.097
∗
NT-proBNP (ng/L) 72 ±63 50 ±34 NS
Echocardiographic parameters: LV EF = left ventricular ejection fraction
E = ﬂow velocity during early diastolic ﬁlling, A = ﬂow velocity during
atrial contraction, late diastolic ﬁlling, E/A = E wave/A wave ratio, A dur
= duration of mitral A-wave, a dur = duration of retrograde a-wave in
pulmonary venous ﬂow, A/a = ratio between the duration of mitral A-wave
and duration of a-wave in pulmonary venous ﬂow, S/D = ratio between
systolic and diastolic pulmonary venous ﬂow, Sm = mitral annulus systolic
tissue velocity, Em = early mitral annulus diastolic tissue velocity, E/Em =
ratio in early mitral diastolic ﬂow and early mitral annulus diastolic tissue
velocity, NT-proBNP = amino terminal pro brain natriuretic peptide, NS-
statistically nonsigniﬁcant, and ∗statistically borderline values.
of left ventricular diastolic dysfunction (E/A and E/Em).
There was a signiﬁcant positive correlation between NT-
proBNP levels and the ratio E/Em(P = .009). The correlation
betweenNT-proBNPlevelsandE/Aratiorevealedborderline
statistical signiﬁcance (P = .091).
4. Discussion
In the control group of 15 patients diagnosed with type
1 GD, there was no evidence of signiﬁcant cardiovascular
manifestations of disease. This is in accordance with current
information from the literature, with the exception of some
clinical case reports [1–6]. The latter usually refer to muta-
tion D409H or the neurological forms of GD. None of our
patients had accompanying cardiovascular diseases, and all
hadnormalphysicalcapabilityfortheirageandnormalsinus
rhythm on electrocardiogram. Taking into consideration
clinical signs and echocardiograhic examinations, none of
the control group had pericardial changes such as pericardial
eﬀusion or constrictive pericarditis. Regarding the data from
the literature, the pericardial involvement could be due to
the organization of hemorrhagic pericardial eﬀusion, yet
patients with Gaucher’s disease have hemorrhagic tendency
[7, 8, 23–25].
During careful examination of the valves, we observed
echocardiographic signs of aortic and/or mitral valve calci-
ﬁcation in three patients. Considering the degrees of calci-
ﬁcation and age of the patients, we can conclude that they
were due to degenerative valvular changes, but this cannot
be conﬁrmed with certainty based only on echocardiograms.
In our patients, there were aortic valve calciﬁcations on the
basal region of the cusps and on the mitral valve ring, which
is quite characteristic for atherosclerotic valvular changes.
In all of our patients, the valves were functionally normal.
We observed mild aortic valve calciﬁcation only in the
oldest patient in the control group. On the basis of only
echocardiographic evidence, it is diﬃcult to conclude the
aetiology of the valvular changes.
None of our patients had signs of pulmonary arte-
rial hypertension or signs of cor pulmonale based on
echocardiographic assessment. This is important because, as
possible trigger for pulmonary artery hypertension in type
1 GD, even enzyme replacement therapy was mentioned.
Namely, there are two reports from the literature describing
four patients with new onset pulmonary artery hyper-
tension after therapy with human placental tissue-derived
alglucerase began [26, 27]. We have found no such data
in the literature regarding therapy with imiglucerase and,
as expected, clinical/echocardiographic data obtained from
our patients proved imiglucerase very likely to be safe. This
can be interpreted with clear structural and manufacturing
diﬀerences between these two drugs. For instance, regarding
alglucerase, no procedure has been shown to be totally
eﬀective in removing viral infectivity, and pulmonary artery
hypertension could be a consequence of unrecognised viral
infection.
We can conclude that none of our patients had pul-
monary hypertension which complies with the clinical
picture of our patients. None of the treated patients had
clinical signs of pulmonary manifestations of GD (symp-
tomatic lung involvement). Also, none had signs of right
ventricular hypertrophy on electrocardiogram. The NT-
proBNP concentrations in our patients were within normal
limits. Elstein et al. proved that NT-proBNP concentrations
in Gaucher disease correlate with the severity of pulmonary
hypertension assessed by the Doppler echocardiography
(tricuspid gradient) [28]. And as it is known that a group of
15 patients are probably too small to compare the incidence
of changes to the pericardium, valves, and pulmonary
arterial hypertension with other authors. In fact, according
to available sources in the literature, such a prospective
echocardiographicstudyhasnotyetbeenperformed.Finally,
the low incidence of Gaucher’s disease poses a serious
obstacle.
Ouraimwastoaccuratelydetermineleftventriculardias-
tolic and systolic function in patients with type 1 GD, which
until now has not yet been systematically researched. Systolic
functionwasevaluatedusingconventionalechocardiography
by calculating the left ventricular ejection fraction and
with tissue Doppler echocardiography. Both methods have
shown normal systolic function that does not diﬀer from
the control group of healthy subjects. Considering the basic
disturbance that could aﬀect the myocardium, since this4 Advances in Hematology
is an inﬁltrative disease (similar to pattern of involvement
that can be seen in the lungs), one would expect left
ventricular diastolic dysfunction [29]. Doppler parameters
showed a tendency towards diastolic dysfunction, but the
diﬀerences between the GD patients and control group
were entirely atypical. Even the most sensitive parameters
of left ventricular diastolic function, Em and E/Em ratio,
using tissue Doppler did not signiﬁcantly conﬁrm diastolic
dysfunction of the left ventricle in the group of GD patients.
We noticed a slight and statistically not signiﬁcant increase
in the E/Em ratio in GD group although it stayed in normal
limits. In general, signiﬁcantly increased E/Em ratio could
be a sign of increased pressure in the left chamber which
is a reﬂection of left ventricular diastolic dysfunction [30–
33].
The most interesting fact is that there is a signiﬁcant
positive correlation between the E/Em ratio and the NT-
proBNP concentration, which is the most sensitive marker
forneurohumoralactivationofheartfailure.Therewasalsoa
nonstatistically signiﬁcant correlation between the E/A ratio
(a parameter for left ventricular relaxation disturbance) and
the NT-proBNP concentration. The NT-proBNP concentra-
tion was within normal limits in both groups.
In the prospective echocardiographic study of type 1 GD
patients, we did not ﬁnd signs of constrictive pericarditis,
pulmonary arterial hypertension, and also there were non
conclusive GD characteristic heart valve changes, which are
most frequently described in GD. We observed some tissue
Doppler parameters that could indicate that GD patients
have left ventricular diastolic dysfunction but the diﬀerences
between GD group and controls did not reach statistical
signiﬁcance. In particular, the E/Em ratio showed a strong
statistical correlation with the most sensitive indicators of
heart failure, NT-proBNP. Based on our results, we cannot
conclude that GD patients develop left ventricular diastolic
dysfunction that can be detected with echocardiography.
Research on larger groups of patients and the usage of
even more sensitive methods as strain rate imaging will be
necessary to conﬁrm eventual myocardial involvement in
GD patients.
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